{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:24Z","timestamp":1788985344213,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis is a chronic, complicated inflammatory skin disease. Genital, nail and scalp lesions with psoriasis are difficult to treat and can considerably impair patients\u2019 quality of life (QoL). Deucravacitinib, an oral selective tyrosine kinase 2 inhibitor, may represent a novel therapeutic option that could improve these challenging manifestations. To investigate this, we conducted a retrospective study between January 2023 and February 2024, involving 70 patients with psoriasis treated with deucravacitinib 6\u2005mg orally once daily for 24 weeks. We evaluated how many patients achieved a static Physician\u2019s Global Assessment (PGA) of Genitalia (sPGA-GTM) score of clear\/almost clear (0\/1), PGA of Fingernail Psoriasis (PGA-F) 0\/1, scalp-specific PGA (ss-PGA) 0\/1, static PGA (sPGA) 0\/1 and Dermatology Life Quality Index 0\/1 at weeks 4, 16 and 24. We also assessed the Psoriasis Area and Severity Index scores. Deucravacitinib improved genital, nail and scalp lesions, as well as systemic eruption and QoL in patients with psoriasis. Deucravacitinib may be a promising treatment option for lesions in difficult-to-treat areas in patients with psoriasis.<\/jats:p>","DOI":"10.1093\/ced\/llae312","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T10:28:36Z","timestamp":1722594516000},"page":"130-133","source":"Crossref","is-referenced-by-count":24,"title":["Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital , Inzai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Onda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital , Inzai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic , Funabashi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-2312","authenticated-orcid":false,"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital , Inzai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2024122223545078300_llae312-B1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/jcm12051934","article-title":"Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis","volume":"12","author":"Hagino","year":"2023","journal-title":"J Clin Med"},{"key":"2024122223545078300_llae312-B2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/jcm12030974","article-title":"Biomarkers and predictive factors for treatment response to tumor necrosis factor-\u03b1 inhibitors in patients with psoriasis","volume":"12","author":"Hagino","year":"2023","journal-title":"J Clin Med"},{"key":"2024122223545078300_llae312-B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024122223545078300_llae312-B4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, \u00addouble-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024122223545078300_llae312-B5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1346-8138.16740","article-title":"Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial","volume":"50","author":"Imafuku","year":"2023","journal-title":"J Dermatol"},{"key":"2024122223545078300_llae312-B6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J Dermatol"},{"key":"2024122223545078300_llae312-B7","doi-asserted-by":"crossref","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2024122223545078300_llae312-B8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","article-title":"Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase 3 randomized, double-blind, \u00adplacebo-controlled trial","volume":"90","author":"Merola","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2024122223545078300_llae312-B9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14712598.2023.2236023","article-title":"Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, \u00adsingle-center, real-life study","volume":"23","author":"Mastorino","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2024122223545078300_llae312-B10","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17252","article-title":"Clinical characteristics and response to biological therapies for inverse psoriasis: a real-life comparison between the therapeutic effects of anti-IL-23 and anti-IL-17 agents","author":"Mastorino","year":"2024","journal-title":"Int J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae312\/59029866\/llae312.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae312\/59029866\/llae312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae312\/59029866\/llae312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T18:55:01Z","timestamp":1734893701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/1\/130\/7726808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,3]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae312","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,3]]}}}